Investor Update

Basel, 11 October 2011

Invitation to Late-stage pipeline event Monday, 7 November 2011

Monday, 7 November 2011

The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London on 7 November 2011 starting at 2pm local time.

The event will provide an opportunity to discuss clinical data and development plans for key late-stage compounds in the Roche development pipeline, including T-DM1 (HER2 franchise) for HER2-positive breast cancer and lebrikizumab (anti-IL13 antibody) for severe asthma.


  • Hal Barron, Head of Global Product Development, Chief Medical Officer

Meeting information (download to my calendar)

To register for the event please follow this link.

This presentation can be viewed through a live video webcast accessed via

Alternatively, dial in to the conference 10-15 min prior to the scheduled start using the following numbers (listen-only mode, no live-access to speakers):

Alternatively a live audio webcast can be accessed via

A replay of the conference call will be available one hour after the conference call, for 48 hours. Access is by dialing:

and will be asked to enter the ID 11854  followed by the # sign.

A replay of the webcast will be available on demand at